Cory Renauer
Value, research analyst, biotech, small-cap

Albany Molecular's Turnaround Train Is Gaining Steam

Feed Albany Molecular Research (NASDAQ:AMRI) money, and it will discover your compounds, or fill your laboratories with temps to discover compounds with you. If that compound enters the clinic, Albany will manufacture small batches for you. If one of those compounds reaches commercial stages, Albany can then large scale manufacture it for you, while collecting royalties. What Albany won't do is funnel its own money into clinical development. Contract discovery and manufacturing services might offer lower margins than clinical development, but there's far less risk.

(click to enlarge)


It took a once in a lifetime credit crunch and some unfortunate acquisitions to derail Albany. After three years of heavy losses, despite reasonably consistent revenues, Albany appears...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details